FDA approves new treatment for adults with relapsed or refractory acute lymphoblastic leukemia FDA approves new Friday August 18th, 2017By Tokio X'press FDA, USA FDA approves new
Opdivo® (Nivolumab) Intravenous Infusion Approved for Supplemental Indication of Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck with Disease Progression on or after Platinum-based Therapy in Taiwan 2017.08.16 Opdivo® (Nivolum Thursday August 17th, 2017By Tokio X'press JPN, Pharmaceutical Opdivo® (Nivolum
Development of new type of antibody utilizing immune reaction contributing to easy detection of dangerous drug components Development of new t Wednesday August 9th, 2017By Tokio X'press Pharmaceutical Development of new t
第一三共、経皮吸収癌疼痛治療剤 フェンタニルクエン酸塩貼付剤 後発医薬品の商業化に向け協業 経皮吸収型持続性癌疼痛治療剤 フェンタニルクエン酸塩貼付剤 Monday August 7th, 2017By Tokio X'press Pharmaceutical 経皮吸収型持続性癌疼痛治療剤 フェンタニルクエン酸塩貼付剤
武田薬品とMolecular社、次世代がん治療薬開発を目指し創薬に関する研究・ライセンス契約の締結 Takeda and Molecular Templa Friday August 4th, 2017By Tokio X'press Pharmaceutical Takeda and Molecular Templa